STOCK TITAN

G1 Therapeutics Inc - GTHX STOCK NEWS

Welcome to our dedicated news page for G1 Therapeutics (Ticker: GTHX), a resource for investors and traders seeking the latest updates and insights on G1 Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect G1 Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of G1 Therapeutics's position in the market.

Rhea-AI Summary
G1 Therapeutics, a commercial-stage oncology company, will release its first quarter 2024 financial results and provide a business update on May 1, 2024. The company will host a webcast and conference call to discuss the financial and corporate performance. Investors can register online to access the live conference call and webcast.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
G1 Therapeutics, Inc. (Nasdaq: GTHX) announces CEO Jack Bailey's presentation at the Needham Virtual Healthcare Conference. The webcast will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.39%
Tags
conferences
-
Rhea-AI Summary
G1 Therapeutics, Inc. grants 3,000 stock options and 1,500 RSUs to a new employee under the Amended and Restated 2021 Plan. The stock options are exercisable at $4.55 per share with a ten-year term, while RSUs vest over four years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.1%
Tags
none
Rhea-AI Summary
G1 Therapeutics, Inc. announced the grant of inducement stock options and restricted stock units to a new employee under their 2021 Inducement Equity Incentive Plan. The stock options are exercisable at $3.73 per share with a ten-year term, while the RSUs vest over four years. These awards are granted as an inducement for the employee to join the company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.88%
Tags
none
-
Rhea-AI Summary
G1 Therapeutics, Inc. achieved $46.3 million in net revenue from sales of COSELA for the full year 2023, representing 48% growth over 2022. They provided 2024 net COSELA revenue guidance of $60 to $70 million. The final analysis of the Phase 3 PRESERVE 2 trial evaluating overall survival in metastatic triple negative breast cancer is estimated to occur in the third quarter of 2024. G1 also presented new analyses indicating improved overall survival with subsequent anticancer therapies for patients who previously received trilaciclib. The company's cash runway extends into 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
38.75%
Tags
-
Rhea-AI Summary
G1 Therapeutics, Inc. CEO to participate in Breast & Lung Cancer Panel Discussion at TD Cowen 44th Annual Health Care Conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.35%
Tags
conferences
Rhea-AI Summary
G1 Therapeutics, Inc. (GTHX) will host a webcast and conference call to provide a financial and corporate update for Q4 and full year 2023 on February 28, 2024. The event will offer insights into the company's performance and future prospects.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.91%
Tags
-
Rhea-AI Summary
G1 Therapeutics, Inc. receives positive recommendation from DMC to continue pivotal Phase 3 trial for trilaciclib in combination with gemcitabine and carboplatin for metastatic triple negative breast cancer, with final analysis expected in Q3 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-53.13%
Tags
-
Rhea-AI Summary
Life Sciences Ontario announces the recipients of its 2024 LSO Awards, recognizing outstanding individuals and companies in the life sciences sector. The awardees include Bill Mantel, Dr. Benjamin Rovinski, Dr. Christine Allen, Dr. Durhane Wong-Rieger, and Satellos Bioscience.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
G1 Therapeutics, Inc. (Nasdaq: GTHX) announced positive preliminary overall survival data from the ongoing Phase 2 trial of trilaciclib in combination with the ADC sacituzumab govitecan (SG) in patients with TNBC. COSELA vial volume grew 19% in the fourth quarter of 2023, and the interim OS analysis of the pivotal 1L TNBC trial for trilaciclib is expected in the first quarter of 2024. The company expects its cash runway to extend into 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.87%
Tags
none
G1 Therapeutics Inc

Nasdaq:GTHX

GTHX Rankings

GTHX Stock Data

237.51M
43.59M
11.68%
30.15%
5.28%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Research Triangle Park

About GTHX

g1 therapeutics is a clinical-stage company developing small-molecule therapies to address significant unmet needs in oncology. the company is leveraging its proprietary kinase drug discovery platform to advance a pipeline of best-in-class compounds and first-in-class drug candidates.